EUH Hunt Conference: What is the prognosis for adenocarcinoma of the lung?

The Bottom Line: There is an overall survival rate of less than 5 years.

  • Stage I: 68-92%
  • Stage II: 53-60%
  • Stage III: 13-36%
  • Stage IV: 0-10%

Reference: DynaMed Plus [Internet]. Ipswich (MA): EBSCO Information Services. 1995 – . Record No. 114774, Non-small cell lung cancer; [updated 2018 May 01, cited 15 May 2018]; [about 31 screens]. Emory access required.

Summary: Five-year survival is only 5-8% in patients with unresectable NSCL cancer. Patients with untreated T1 tumors have a survival rate of 9%. Five-year mortality is higher in men than in women.

5-year survival for patients with lung and bronchus cancer by stage at diagnosis:

  • 18% with disease at all stages
  • 55% with localized disease
  • 28% with regional disease
  • 4% with distant stage disease

A study considering intervention and age found that older age and less intervention is associated with poorer survival:

  • > 80 years: 47% no radiation/surgery, 7.4% 5-year survival
  • 70-79 years: 28% no radiation/surgery, 12.3% 5-year survival
  • < 70 years: 19% no radiation/surgery, 15.5% 5-year survival

Additional Information: DynaMed Plus provides breakdowns by stage, age, and other factors.

For information on the staging of lung cancer, see the IASLC Lung Cancer Staging Project.